Q2'19 EARNINGS CALL





SAFE HARBOR STATEMENT

This presentation contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including statements about estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of July 30, 2019 and expressly disclaims any duty to update information contained in this presentation.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, we could become subject to significant sanctions. While we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to acquire other companies or products and to integrate the operations of companies we have acquired may not be successful. A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all,

This presentation includes GAAP and non-GAAP financial measures. In accordance with the requirements of SEC Regulation G, reconciliations between these two measures, if these slides are in hard copy, accompany the hard copy presentation or, if these slides are delivered electronically, are available on the Company's website at www.amgen.com within the Investors section.



AGENDA

Introduction	Arvind Sood
Opening Remarks	Bob Bradway
Q2 '19 Business Results	David Meline
Global Commercial Review	Murdo Gordon
R&D Review	David Reese
Q&A	All



INVESTING FOR LONG-TERM GROWTH

- We are executing well in an increasingly dynamic healthcare environment
- We are managing our portfolio of products effectively and delivering strong volume-driven growth
- We continue to work with the Administration, Congress and the entire healthcare community to advocate for solutions to the drug pricing debate
- Our biosimilars are well positioned to contribute to our long-term growth and we recently launched in the U.S.
- We continue to make significant investments in Research and Development to advance a pipeline of differentiated, first-in-class programs
- We are focused on delivering long-term growth for our shareholders



Q2'19 BUSINESS RESULTS

DAVID MELINE EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER



NON-GAAP EPS IS UP 4% IN Q2 2019

\$ Millions, Except Non-GAAP EPS

ltem	Q2 '19	Q2 '18	B/(W) %
Revenue Product Sales Other Revenues	\$5,871 5,574 297	\$6,059 5,679 380	(3)% (2)%
Non-GAAP Operating Expenses	2,898	2,928	1%
Cost of Sales % of product sales	736 13.2%	745 13.1%	
R&D % of product sales	906 16.3%	850 15.0%	
SG&A % of product sales	1,256 22.5%	1,333 23.5%	
Non-GAAP Operating Income % of product sales	2,973 53.3%	3,131 55.1%	(5)%
Other Income/(Expense)	(114)	(185)	
Non-GAAP Net Income	\$2,423	\$2,529	(4)%
Non-GAAP EPS	\$3.97	\$3.83	4%
Average Shares (millions)	610	660	8%
Non-GAAP Tax Rate	15.3%	14.2%	(1.1) pts

All income statement items for Q2 '19 and/or Q2 '18, except revenue, other income/(expense) and average shares, are non-GAAP financial measures—if this slide is in hard copy, see reconciliations accompanying the presentation, or if this slide is delivered electronically, see reconciliations available at: www.amgen.com within the Investors section

Provided July 30, 2019, as part of an oral presentation and is qualified by

such, contains forward-looking statements, actual results may vary



STRONG BALANCE SHEET WITH FREE CASH FLOW OF \$1.3B IN Q2 2019

\$ Billions

Cash Flow Data	Q2 '19	Q2 '18
Capital Expenditures	\$0.1	\$0.2
Free Cash Flow*	1.3	1.9
Share Repurchase	2.3	3.2
Dividends Paid	0.9	0.9
Balance Sheet Data	Q2 '19	Q2 '18
Cash and Investments	21.8	29.4
Debt Outstanding	30.6	34.5

*Non-GAAP financial measure—if this slide is in hard copy, see reconciliations accompanying the presentation, or if this slide is delivered electronically, see reconciliations available at: www.amgen.com within the Investors section

Provided July 30, 2019, as part of an oral presentation and is qualified by

such, contains forward-looking statements, actual results may vary



2019 GUIDANCE REVISED UPWARD

	Updated Guidance	Previous Guidance
Revenue	\$22.4B-\$22.9B	\$22.0B-\$22.9B
Non-GAAP EPS*	\$13.75–\$14.30	\$13.25-\$14.30
Non-GAAP Tax Rate*	14%–15%	14%–15%
Capital Expenditures	~ \$700M	~ \$700M

*Non-GAAP financial measure—if this slide is in hard copy, see reconciliations accompanying the presentation, or if this slide is delivered electronically, or amounts pertain to previously issued financial guidance, see reconciliations available at: www.amgen.com within the Investors section

Provided July 30, 2019, as part of an oral presentation and is qualified by

such, contains forward-looking statements, actual results may vary

GLOBAL COMMERCIAL REVIEW

MURDO GORDON EXECUTIVE VICE PRESIDENT, GLOBAL COMMERCIAL OPERATIONS



Q2'19 GLOBAL COMMERCIAL REVIEW

C Millione Net Cales		Q2 '19	Q2 '18	YoY 🛆	
\$ Millions, Net Sales	U.S.	ROW	Total	Total	Total
Repatha [®]	\$91	\$61	\$152	\$148	3%
Prolia [®]	458	240	698	610	14%
EVENITY [™]	3	25	28	-	NM
Aimovig [®]	83	-	83	2	NM
Parsabiv [®]	148	20	168	73	130%
KYPROLIS [®]	166	101	267	263	2%
XGEVA [®]	379	120	499	452	10%
Vectibix [®]	79	117	196	173	13%
Nplate [®]	122	79	201	179	12%
BLINCYTO [®]	39	39	78	60	30%
Enbrel [®]	1,315	48	1,363	1,302	5%
Neulasta [®]	719	105	824	1,100	(25%)
NEUPOGEN®	55	20	75	102	(26%)
EPOGEN®	223	_	223	250	(11%)
Aranesp [®]	192	244	436	472	(8%)
Sensipar [®] /Mimpara [®]	43	79	122	420	(71%)
Biosimilars*	-	82	82	2	NM
Other**	27	52	79	71	11%
Total Product Sales	\$4,142	\$1,432	\$5,574	\$5,679	(2%)
Total Revenues			\$5,871	\$6,059	(3%)

10

materially; Amgen disclaims any duty to update.


NM = not meaningful *Biosimilars includes AMGEVITA[™] and KANJINTI[™] **Other includes Bergamo, MN Pharma, IMLYGIC[®] and Corlanor[®]

Provided July 30, 2019, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary

AMGEN

Q2'19 PRODUCT SALES

\$ Millions, Net Sales



Q2 Highlights

- Volume driven growth from new and recently launched products
- International sales grew 14% YoY, excluding the impact of foreign exchange,* driven by 18% volume growth
- Competing effectively with our more mature brands

*Non-GAAP financial measure—if this slide is in hard copy, see reconciliations accompanying the presentation, or if this slide is delivered electronically, see reconciliations available at: www.amgen.com within the Investors section Note: Inventory represents wholesaler and, based on prescription data for Enbrel[®], end-user inventories

Provided July 30, 2019, as part of an oral presentation and is qualified by


such, contains forward-looking statements, actual results may vary





Q2'19 REPATHA® SALES GREW 3% YOY

\$ Millions, Net Sales



Highlights

- YoY growth driven primarily by unit volume, offset partially by net selling price* with 66% volume growth in U.S.
- Low list price Repatha[®]
 - Currently available to ~ 70% of Medicare patients
 - Only 7% of Medicare patients have access at low copay tier
- Blended U.S. net price declined and is impacting near-term sales
- We expect unit volume and sales growth over the longer term


*Net selling price represents the impact of a 60% reduction in list price as well as contracting and access changes Note: Inventory represents wholesaler inventories





Q2'19 PROLIA® SALES GREW 14% YOY

\$ Millions, Net Sales



Highlights

- Strong YoY performance with double-digit unit volume growth
- Double-digit YoY new patient growth in U.S.
- QoQ growth follows typical Prolia[®] seasonality


Note: Inventory represents wholesaler inventories





EVENITY[™] OFFERS A NEW ALTERNATIVE IN OSTEOPOROSIS

\$ Millions, Net Sales



Highlights

- Osteoporosis is a global epidemic, and in the U.S. alone is responsible for
 2 million frontures per year
 - ~ 2 million fractures per year
- Early launch feedback has been positive with strong uptake in Japan


Note: Inventory represents wholesaler inventories





AIMOVIG® IS THE LEADER WITHIN ITS CLASS

\$ Millions, Net Sales



Highlights


- Aimovig[®] remains the segment leader and to date
 - ~ 225,000 patients prescribed
 - ~ 1M prescriptions filled
 - ~ 27,000 prescribers
- Paid prescriptions increased to over 70% in Q2 versus ~ 60% in Q1
- We expect net selling price* to remain relatively stable
- Recently launched single 140 mg/mL monthly auto-injector

Aimovig[®] is developed in collaboration with Novartis; *Net selling price represents the impact of list price changes as well as contracting and access changes Note: Inventory represents wholesaler inventories; CGRP = calcitonin gene-related peptide



Q2 '19 HEMATOLOGY/ONCOLOGY* SALES GREW 10% YOY

\$ Millions, Net Sales



Highlights

- Sales totaled \$1.3 billion
- Double-digit YoY growth driven by unit volume growth
- All products in the U.S. grew double-digits


*Includes Vectibix®, Nplate®, XGEVA®, KYPROLIS®, BLINCYTO® and IMLYGIC® Note: Inventory represents wholesaler inventories





Q2'19 XGEVA® SALES GREW 10% YOY

\$ Millions, Net Sales



Highlights

- YoY growth driven primarily by unit volume growth
- Rapid growth in multiple myeloma patients


Note: Inventory represents wholesaler inventories



Q2 '19 KYPROLIS® SALES GREW 2% YOY



\$ Millions, Net Sales



Highlights

- Double-digit volume growth in the U.S. driven by strong demand
- YoY declines in ROW due to a \$27M clinical trial purchase in Q2 '18


Note: Inventory represents wholesaler inventories; ROW = Rest of World



Q2 '19 ENBREL® SALES GREW 5% YOY



\$ Millions, Net Sales



Highlights

- YoY sales growth driven primarily by net selling price* benefits and favorable changes in inventory levels, offset partially by lower unit demand
- Expect volume trends to continue


*Net selling price represents the impact of list price changes as well as contracting and access changes Note: Inventory represents wholesaler and, based on prescription data, end-user inventories





Q2 '19 NEULASTA® SALES DECREASED 25% YOY

\$ Millions, Net Sales



Highlights

- YoY sales decrease driven by lower net selling price* and the impact of biosimilar competition on unit demand
- Exited Q2 with ~ 80% share of the long-acting segment
- Onpro[®] units stable QoQ

*Net selling price represents the impact of list price changes as well as contracting and access changes Note: Inventory represents wholesaler inventories



Q2'19 EPOGEN® SALES DECLINED 11% YOY



\$ Millions, Net Sales



Highlights

- YoY sales decline primarily due to lower net selling price*
- Net selling price* will continue to decline in 2019 due to extended supply agreement with DaVita


*Net selling price represents the impact of list price changes as well as contracting and access changes Note: Inventory represents wholesaler inventories





Q2 '19 ARANESP® SALES DECLINED 8% YOY

\$ Millions, Net Sales



Highlights

- YoY decline driven by the impact of competition on unit demand
- Expect YoY sales to decline at a faster rate in 2019 versus 2018 due to competition


Note: Inventory represents wholesaler inventories



Q2 '19 PARSABIV[®] SALES CONTINUED ON A SOLID TRAJECTORY



\$ Millions, Net Sales



Highlights

- Solid growth with sales more than doubling YoY
- Strong utilization at independent and midsize dialysis providers
- Large dialysis organizations continue to increase adoption gradually


Note: Inventory represents wholesaler inventories





Q2 '19 SENSIPAR® SALES DECREASED 71% YOY

\$ Millions, Net Sales



Highlights


- YoY decrease driven by at-risk, small molecule generic launches
- Outlook remains uncertain given ongoing legal proceedings

Note: Inventory represents wholesaler inventories



BIOSIMILARS OFF TO A STRONG START AND REPRESENT A MEANINGFUL GROWTH OPPORTUNITY

\$ Millions, Net Sales



Highlights

- Launches of KANJINTI™ and AMGEVITA™ outside the U.S. annualizing at > \$300M
- Recently launched biosimilars in the U.S. with KANJINTI™ and MVASI™

Note: Inventory represents wholesaler inventories



R&D REVIEW

DAVID REESE, M.D. EXECUTIVE VICE PRESIDENT, RESEARCH AND DEVELOPMENT



Q2'19 R&D UPDATE

Research

- Intermountain Healthcare collaboration
 - Combines Intermountain's internationally-recognized expertise in precision medicine and clinical care with deCODE Genetics' world-class expertise in human population genetics
 - Largest and most comprehensive DNA mapping effort to date in the U.S. from a single population will add 500,000 DNA samples to deCODE Genetics' database
- Nuevolution acquisition
 - Integrating world-class DNA-encoded library and other technologies



Q2 '19 R&D UPDATE

Cardiovascular

- Omecamtiv mecarbil—myosin activator
 - Completed enrollment in Phase 3 cardiovascular outcomes study (GALACTIC-HF)
- AMG 890—Lp(a) siRNA
 - Enrolling patients with elevated Lp(a) in Phase 1 study
 - Anticipate launching next phase of development in H1 '20

Inflammation

- AMG 570—ICOSL-BAFF bispecific antibody-peptide conjugate
 - Moving into Phase 2 development in Systematic Lupus Erythematosus

Bone

- EVENITY™
 - Request for re-examination of CHMP negative opinion submitted by UCB

Lp(a) = lipoprotein(a); siRNA = short interfering ribonucleic acid; ICOSL = Inducible T cell costimulator ligand; BAFF = B cell activating factor; CHMP = Committee for Medicinal Products for Human Use; EVENITY[™] is developed in collaboration with UCB globally, as well as our joint venture partner Astellas in Japan; Omecamtiv mecarbil is being developed under a collaboration between Amgen and Cytokinetics, with funding and strategic support from Servier



Q2 '19 R&D UPDATE

Oncology

- AMG 510—KRAS G12C inhibitor
 - First-in-human lung cancer data update at the IASLC World Conference on Lung Cancer
 - Tumor responses also seen in colorectal and appendiceal patients
 - Enrollment completed in monotherapy arm of dose expansion study
 - Enrolling patients in PD-1 combination arm of dose expansion study
 - Initiating potential registration enabling monotherapy study in 2019
- CAR T programs

materially: Amgen disclaims any duty to update.

- Paused FLT3 and DLL3 programs; HLE-BiTE[®] programs for both targets ongoing

Provided July 30, 2019, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary

IASLC = International Association for the Study of Lung Cancer; PD-1 = programmed cell death protein 1; CAR T = chimeric antigen receptor enhanced T cells; FLT3 = fms-like tyrosine kinase 3; DLL3 = delta-like 3; HLE = half-life extended

Q2'19 R&D UPDATE

Biosimilars

- KANJINTI™ (biosimilar trastuzumab)
 - Approved by FDA for all approved indications of Herceptin[®]
- ABP 798 (biosimilar rituximab)
 - Phase 3 data in non-Hodgkin's lymphoma expected Q3 '19
- ABP 710 (biosimilar infliximab)
 - FDA has set a December 14, 2019 Biosimilar User Fee Act target action date



DATA EXPECTED FROM MANY NOVEL, HIGH-POTENTIAL ONCOLOGY PROGRAMS

Multiple Myeloma	Leukemia/Lympho	ma	Solid Tumors				
KYPROLIS [®] proteasome inhibitor	BLINCYTO [®] CD19 BiTE [®]	ALL	IMLYGIC [®] oncolytic virus	Melanoma			
AMG 420 BCMA BITE®	AMG 562 CD19 HLE-BITE®	NHL	AMG 509* prostate bispecific Ab (XmAb [®])	Prostate			
AMG 701 BCMA HLE-BITE®	AMG 330 CD33 BiTE [®]		AMG 160* PSMA HLE-BITE®				
AMG 424 CD38 bispecific Ab (XmAb [®])	AMG 673 CD33 HLE-BiTE®		AMG 757 DLL3 HLE-BiTE®	Small Cell			
AMG 176 MCL-1 inhibitor (iv)	AMG 427 FLT3 HLE-BiTE®	AML	AMG 119 DLL3 CAR T	Lung Cancer			
AMG 397 MCL-1 inhibitor (oral)	AMG 553* FLT3 CAR T		AMG 510 KRAS G12C inhibitor	Solid Tumors			
Data expected 2019	AMG 176 MCL-1 inhibitor (iv)		AMG 199* HLE-BiTE [®]	Gastric			
	AMG 397 MCL-1 inhibitor (oral)		AMG 910* HLE-BiTE [®]	Gasine			
Data possible 2019			AMG 596 EGFRviii BiTE®	Glioblastoma			

*Not yet enrolling patients; HLE = half-life extended; Ab = antibody; Mcl-1 = myeloid cell leukemia-1; iv = intravenous; FLT3 = fms-like tyrosine kinase 3; CAR T = chimeric antigen receptor enhanced T cells; NHL = non-Hodgkin's lymphoma; AML = acute myeloid leukemia; PSMA = prostate-specific membrane antigen; DLL3 = delta-like 3; EGFR viii = epithelial growth factor receptor variant iii





Q2'19 EARNINGS CALL





RECONCILIATIONS



Amgen Inc. Consolidated Statements of Income - GAAP (In millions, except per-share data) (Unaudited)

		Three months ended June 30,			Six monti June			ths ended e 30,	
	_	2019		2018		2019		2018	
Revenues:									
Product sales	\$	5,574	\$	5,679	\$	10,860	\$	11,02	
Other revenues		297		380		568		59	
Total revenues		5,871		6,059		11,428	_	11,61	
Operating expenses:									
Cost of sales		1,012		1,024		2,067		1,96	
Research and development		924		869		1,803		1,62	
Selling, general and administrative		1,260		1,353		2,414		2,48	
Other		(3)		(19)		(6)		(2	
Total operating expenses	_	3,193	_	3,227		6,278	_	6,05	
Operating income		2,678		2,832		5,150		5,55	
Interest expense, net		332		347		675		68	
Interest and other income, net		218		162		403		39	
Income before income taxes		2,564		2,647		4,878		5,26	
Provision for income taxes		385		351		707		65	
Net income	\$	2,179	\$	2,296	\$	4,171	\$	4,60	
Earnings per share:									
Basic	\$	3.59	\$	3.50	\$	6.78	\$	6.7	
Diluted	\$	3.57	\$	3.48	\$	6.75	\$	6.7	
Weighted-average shares used in calculation of earnings per share	:								
Basic		607		656		615		68	
Diluted		610		660		618		68	
of an oral presentation and is qualified by									
g statements, actual results may vary 34									

Provided July 30, 2019, as part such, contains forward-looking materially; Amgen disclaims any duty to update.

Amgen Inc. Consolidated Balance Sheets - GAAP (In millions)

June 30, 2019 (Unaudited)		Dec	cember 31, 2018	
Assets		,		
Current assets:				
Cash, cash equivalents and marketable securities	\$	21,758	\$	29,304
Trade receivables, net		3,801		3,580
Inventories		3,176		2,940
Other current assets		2,011		1,794
Total current assets		30,746		37,618
Property, plant and equipment, net		4,882		4,958
Intangible assets, net		6,813		7,443
Goodwill		14,689		14,699
Other assets		2,243		1,698
Total assets	\$	59,373	\$	66,416
Liabilities and Stockholders' Equity Current liabilities:				
Accounts payable and accrued liabilities	\$	7,806	¢	9,069
Current portion of long-term debt	Φ	2,816	φ	9,009 4,419
Total current liabilities		10,622		13,488
Long-term debt		27,798		29,510
Long-term deferred tax liabilities		763		864
Long-term tax liabilities		7,861		8,770
Other noncurrent liabilities		1,535		1,284
Total stockholders' equity		10,794		12,500
Total liabilities and stockholders' equity	\$	59,373	\$	66,416
Shares outstanding		602		630



Amgen Inc. GAAP to Non-GAAP Reconciliations

		_	oun	c oo,			Udin	c 00,
(Dollars in millions	CAAB cost of color	\$	2019 1,012	\$	2018 1,024	\$	2019 2,067	\$
(Dollars in millions	Adjustments to cost of sales:	φ	1,012	φ	1,024	φ	2,007	φ
(Unaudited)	Acquisition-related expenses (a)		(276)		(279)		(552)	
(Onaudited)	Total adjustments to cost of sales		(276)		(279)		(552)	
	Non-GAAP cost of sales	\$	736	\$	745	\$	1,515	\$
	GAAP cost of sales as a percentage of product sales		18.2%	_	18.0%		19.0%	_
	Acquisition-related expenses (a)		-5.0		-4.9		-5.0	
	Non-GAAP cost of sales as a percentage of product sales		13.2%		13.1%		14.0%	
	GAAP research and development expenses	\$	924	\$	869	\$	1,803	\$
	Adjustments to research and development expenses:							
	Acquisition-related expenses (a)		(18)		(19)		(38)	
	Total adjustments to research and development expenses		(18)		(19)		(38)	
	Non-GAAP research and development expenses	\$	906	\$	850	\$	1,765	\$
	GAAP research and development expenses as a percentage of product sales		16.6%		15.3%		16.6%	
	Acquisition-related expenses (a)		-0.3		-0.3		-0.3	
	Non-GAAP research and development expenses as a percentage of product sales	_	16.3%		15.0%	_	16.3%	_
	GAAP selling, general and administrative expenses	\$	1,260	\$	1,353	\$	2,414	\$
	Adjustments to selling, general and administrative expenses:							
	Acquisition-related expenses (a)		(5)		(20)		(9)	
	Certain net charges pursuant to our restructuring initiative		1		_		_	
	Total adjustments to selling, general and administrative expenses		(4)		(20)		(9)	
	Non-GAAP selling, general and administrative expenses	\$	1,256	\$	1,333	\$	2,405	\$
	GAAP selling, general and administrative expenses as a percentage of product sales		22.6%		23.8%		22.2%	
	Acquisition-related expenses (a)		-0.1		-0.3		-0.1	
	Certain net charges pursuant to our restructuring initiative		0.0		0.0		0.0	
	Non-GAAP selling, general and administrative expenses as a percentage of product sales		22.5%		23.5%		22.1%	_
	GAAP operating expenses	\$	3,193	\$	3,227	\$	6,278	\$
	Adjustments to operating expenses:							
	Adjustments to cost of sales		(276)		(279)		(552)	
	Adjustments to research and development expenses		(18)		(19)		(38)	
	Adjustments to selling, general and administrative expenses		(4)		(20)		(9)	
	Certain net charges pursuant to our restructuring initiative		1		7		2	
	Certain other expenses		-		(25)		_	
	Acquisition-related adjustments		2		37		4	
	Total adjustments to operating expenses	_	(295)	_	(299)	_	(593)	_
	Non-GAAP operating expenses	\$	2,898	\$	2,928	\$	5,685	\$
	GAAP operating income	\$	2,678	\$	2,832	\$	5,150	\$
	Adjustments to operating expenses		295		299		593	
	Non-GAAP operating income	\$	2,973	\$	3,131	\$	5,743	\$
	GAAP operating income as a percentage of product sales		48.0%		49.9%		47.4%	
	Adjustments to cost of sales		5.0		4.9		5.0	
	Adjustments to research and development expenses		0.3		0.3		0.3	
	Adjustments to selling, general and administrative expenses		0.1		0.3		0.1	
	Certain net charges pursuant to our restructuring initiative		0.0		0.0		0.0	
	Certain other expenses		0.0		0.4		0.0	
	Acquisition-related adjustments		-0.1		-0.7		0.1	
	Non-GAAP operating income as a percentage of product sales	_	53.3%		55.1%		52.9%	

Provided July 30, 2019, as part of an oral presentation and is qualified by such, contains forward-looking statements, actual results may vary materially; Amgen disclaims any duty to update.

		Three months ended June 30,			Six months ended June 30,			
		2019		2018		2019		2018
GAAP interest and other income, net	\$	218	\$	162	\$	403	\$	393
Adjustments to other income (b)		_		_		_		(75)
Non-GAAP interest and other income, net	\$	218	\$	162	\$	403	\$	318
GAAP income before income taxes	\$	2,564	\$	2,647	\$	4,878	\$	5,266
Adjustments to operating expenses		295		299		593		611
Adjustments to other income (b)		_		_		_		(75)
Non-GAAP income before income taxes	\$	2,859	\$	2,946	\$	5,471	\$	5,802
GAAP provision for income taxes	\$	385	\$	351	\$	707	\$	659
Adjustments to provision for income taxes:								
Income tax effect of the above adjustments (c)		70		74		138		138
Other income tax adjustments (d)		(19)		(8)		(27)		10
Total adjustments to provision for income taxes		51		66		111		148
Non-GAAP provision for income taxes	\$	436	\$	417	\$	818	\$	807
GAAP tax as a percentage of income before taxes		15.0%	,	13.3%	13.3% 14.5%			12.5%
Adjustments to provision for income taxes:								
Income tax effect of the above adjustments (c)		0.9		1.2		1.0		1.2
Other income tax adjustments (d)		-0.6		-0.3		-0.5		0.2
Total adjustments to provision for income taxes		0.3		0.9		0.5		1.4
Non-GAAP tax as a percentage of income before taxes	_	15.3%		14.2%		15.0%		13.9%
GAAP net income	\$	2,179	\$	2,296	\$	4,171	\$	4,607
Adjustments to net income:								
Adjustments to income before income taxes, net of the income tax effect		225		225		455		398
Other income tax adjustments (d)		19		8	27		(10)	
Total adjustments to net income		244		233		482		388
Non-GAAP net income	\$	2,423	\$	2,529	\$	4,653	\$	4,995



Three months ended

June 30,

Six months ended

June 30, 2018

1,968

(545)

(545) 1,423

17.9%

-5.0

12.9%

(40)

(40)

1,589 14.8%

-0.4

14.4%

(45) (3)

(48)

22.5%

-0.4

0.0 22.1%

6,055 (545) (40) (48) 6 (25) 41 (611) 5,444 5,558 611 6,169 50.4% 5.0 0.4 0.4 0.0 0.2 -0.4 56.0%

2,432

2,480

1,629

Amgen Inc. GAAP to Non-GAAP Reconciliations (In millions, except per-share data) (Unaudited)

The following table presents the computations for GAAP and non-GAAP diluted earnings per share:

		Three months ended June 30, 2019				ended 18		
	_	GAAP	No	on-GAAP		GAAP	N	on-GAAP
Net income	\$	2,179	\$	2,423	\$	2,296	\$	2,529
Weighted-average shares for diluted EPS		610		610		660		660
Diluted EPS	\$	3.57	\$	3.97	\$	3.48	\$	3.83
		Six mon June 3			Six months ended June 30, 2018			
		GAAP	No	on-GAAP		GAAP	N	on-GAAP
Net income	\$	4,171	\$	4,653	\$	4,607	\$	4,995
Weighted-average shares for diluted EPS		618		618		685		685

(a) The adjustments related primarily to noncash amortization of intangible assets acquired in business combinations.

(b) For the six months ended June 30, 2018, the adjustment related to the net gain associated with the Kirin-Amgen share acquisition.

- (c) The tax effect of the adjustments between our GAAP and non-GAAP results takes into account the tax treatment and related tax rate(s) that apply to each adjustment in the applicable tax jurisdiction(s). Generally, this results in a tax impact at the U.S. marginal tax rate for certain adjustments, including the majority of amortization of intangble assets, whereas the tax impact of other adjustments, including restructuring expense, depends on whether the amounts are deductible in the respective tax jurisdictions and the applicable tax rate(s) in those jurisdictions. Due to these factors, the effective tax rates for the adjustments to our GAAP income before income taxes, for the three and six months ended June 30, 2019, were 23.7% and 23.3%, compared with 24.7% and 25.7% for the corresponding periods of the prior year.
- (d) The adjustments related primarily to certain acquisition items and priorperiod items excluded from GAAP earnings.



Amgen Inc. Reconciliations of Cash Flows (In millions) (Unaudited)

Net cash provided by operating activities Net cash provided by investing activities Net cash used in financing activities (Decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period

Three mor Jun		Six months ended June 30,				
 2019	2018		2019		2018	
\$ 1,414	\$ 2,102	\$	3,259	\$	4,829	
2,745	2,938		6,300		17,844	
(5,992)	(4,650)		(10,979)		(16,342)	
(1,833)	390		(1,420)		6,331	
7,358	9,741		6,945		3,800	
\$ 5,525	\$ 10,131	\$	5,525	\$	10,131	

Net cash provided by operating activities
Capital expenditures
Free cash flow

_	Three months ended June 30,				Six months ended June 30,			
	2019		2018	2019		2018		
\$	1,414	\$	2,102	\$	3,259	\$	4,829	
	(144) (187)			(260)	(342)			
\$	1,270	\$	1,915	\$	2,999	\$	4,487	



Reconciliation of GAAP EPS Guidance to Non-GAAP EPS Guidance for the Year Ending December 31, 2019 (Unaudited)

GAAP diluted EPS guidance	\$12.10		\$12.71
Known adjustment to arrive at non-GAAP*:			
Acquisition-related expenses (a)	1.55		1.61
Tax adjustments		0.04	
Non-GAAP diluted EPS guidance	\$13.75		\$14.30

* The known adjustments are presented net of their related tax impact, which amount to approximately \$0.38 per share.

(a) The adjustments relate primarily to non-cash amortization of intangible assets acquired in business combinations.

Our GAAP diluted EPS guidance does not include the effect of GAAP adjustments triggered by events that may occur subsequent to this press release such as acquisitions, asset impairments, litigation and changes in the fair value or our contingent consideration.

Reconciliation of GAAP Tax Rate Guidance to Non-GAAP Tax Rate Guidance for the Year Ending December 31, 2019 (Unaudited)

GAAP tax rate guidance	13%	_	14%
Tax rate of known adjustments discussed above		1%	
Non-GAAP diluted EPS guidance	14%	_	15%



Amgen Inc. International Sales Performance Adjusted for Foreign Exchange

Amgen has presented international sales performance excluding the impact of foreign exchange. This measure adjusts for the translation effect of changes in average foreign exchange rates between the current period and the corresponding period in the prior year. Amgen's calculation to adjust for the impact of foreign exchange results in prior period weighted-average, foreign exchange rates being applied to current period product sales. Amgen believes that excluding the impact of foreign exchange enhances an investor's overall understanding of the financial performance and prospects for the future of Amgen's core business activities by facilitating comparisons of results of core business operations among current, past and future periods.



Q2'19 EARNINGS CALL



